AMI and Multivessel Disease: Can We Perform a Single Procedure?

Percutaneous coronary intervention (PCI) is considered the treatment of choice in ST-segment elevation myocardial infarction (STEMI). However, it is widely acknowledged that, in many cases, there are significant lesions in other coronary arteries. Previous randomized studies have shown that complete revascularization in a second procedure is more beneficial than intervention only in the culprit artery.

IAM y múltiples vasos, ¿podemos realizar un solo procedimiento?

However, there is still no conclusive evidence to support PCI in the other coronary arteries during the same procedure.

The MULTISTAR Trial addressed this issue by including 840 patients with STEMI who were hemodynamically stable and had lesions in multiple coronary vessels. Of these patients, 418 underwent primary PCI along with immediate PCI of severe lesions in other coronary arteries (PCI I), while 422 underwent PCI only in the culprit artery, deferring intervention in severe lesions in the rest of the vessels (PCI D). This second intervention took place between day 19 and day 45 after the event. It is worth noting that researchers used third-generation SYNERGY stent, from Boston Scientific.

The primary endpoint (PEP) of the MULTISTAR Trial consisted of a set of events that included death from any cause, non-fatal acute myocardial infarction, stroke, unplanned revascularization due to ischemia, or hospitalization for heart failure within one year from randomization.

Read also: TRILUMINATE Two Years In: Encouraging Results.

The average age of the participants was 75 years, and most of them were men. Additionally, 50% of patients had hypertension, 15% had diabetes, 6% had undergone a prior PCI, 5% had experienced a prior acute myocardial infarction, 2% had suffered a stroke, 2% had peripheral vascular disease, and 4% had experienced cardiac arrest before arriving at the hospital.

The most common location of acute myocardial infarction was the anterior region (40%), followed by the inferior (11%), lateral, and posterior.

Transradial access was the most frequently used (72%). There were no significant differences between the two groups regarding the procedure, the culprit artery, the lesions in multiple vessels, or the stents used. The use of intravascular imaging techniques (IVUS, OCT) or the assessment of coronary physiology were infrequent.

Read also: BIFURCAT Registry: Long Term Diabetes Impact on Bifurcations PCI Outcomes.

Regarding the primary endpoint at 12 months, PCI I was not inferior to PCI D as a strategy. The event rate was 8.5% in the PCI I group and 13.6% in the PCI D group, with a hazard ratio of 0.52 (95% confidence interval, 0.38 to 0.72; p < 0.001 for non-inferiority and p < 0.001 for superiority). Additionally, there were no significant differences in terms of all-cause death, non-fatal acute myocardial infarction, stroke, ischemia-guided revascularization, or hospitalization for heart failure between the two groups.

Conclusion

In summary, in hemodynamically stable patients with AMI and lesions in multiple coronary arteries, immediate PCI was not inferior compared with its deferral, in terms of all-cause death, non-fatal acute myocardial infarction, stroke, ischemia-guided revascularization, or hospitalization for heart failure during a one-year period.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction.

Reference: B.E. Stähli, et al. NEJM DOI: 10.1056/NEJMoa2307823.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...